Levothyroxine
Synthetic T4 replacement for hypothyroidism
For overt hypothyroidism, levothyroxine is highly effective and confidence is high. For subclinical hypothyroidism — a raised TSH with normal free T4 — trial evidence, particularly in older adults, shows no symptom benefit, and routine treatment is not supported.
How confident is BioSignal?
Our overall position, and how sure we are of it across each dimension — including where we are not sure at all.
High confidence
For overt hypothyroidism, levothyroxine is highly effective and confidence is high. For subclinical hypothyroidism — a raised TSH with normal free T4 — trial evidence, particularly in older adults, shows no symptom benefit, and routine treatment is not supported.
Well-supported by consistent, high-quality evidence.
Biological Role
Levothyroxine is identical to the T4 the thyroid produces, and the body converts it to active T3. Replacement restores normal physiology rather than mimicking it.
Human Evidence
Decades of clinical use plus randomised evidence, including trials that specifically examined the subclinical population.
Benefit In Overt Disease
Restores thyroid function and resolves symptoms. One of the clearest benefit-to-cost ratios in medicine.
Benefit In Subclinical Disease
The TRUST trial found no improvement in symptoms or tiredness in older adults with subclinical hypothyroidism. Treating the number is not the same as treating the person.
Safety Confidence
Very safe when correctly dosed. The risk is over-replacement — which causes atrial fibrillation and bone loss, and is common.
Research Activity
Focused on the persistent-symptoms problem, the role of T3, and who actually benefits from treating subclinical disease.
Where the evidence stands today
How mature the science is, what kinds of evidence exist, and — the part nobody else prints — what is still missing.
9/9
steps proven in humans
Evidence-rich
Proven at every applicable step — rare, and worth noticing.
Guideline / regulatory support
ProvenRecommended as monotherapy of choice.
Clinical outcomes
ProvenSymptom resolution in overt disease; no benefit shown in subclinical.
Large human RCTs
ProvenIncluding TRUST in subclinical disease.
Small human outcome trials
ProvenSymptom outcomes.
Human safety data
ProvenDecades of use; risks of over-replacement well characterised.
Human biomarker / pharmacology
ProvenReliable normalisation of TSH and free T4.
Animal
ProvenExtensive.
Cell / in vitro
ProvenThyroid hormone receptor biology established.
Mechanistic plausibility
ProvenIdentical to endogenous T4; restores normal physiology.
The bottom line
What we know, what we think, what we don't know — and what would change our mind.
What We Know
Overt hypothyroidism — a raised TSH with a low free T4 — is effectively treated by levothyroxine. This is settled, and the drug is cheap and safe when properly dosed.
What We Think
Subclinical hypothyroidism is over-treated. When a raised TSH sits alongside a normal free T4, treatment often delivers no symptom benefit while exposing the patient to the risks of over-replacement.
What We Don't Know
Why a genuine subset of patients continue to feel unwell on levothyroxine despite a normal TSH. This problem is real, it is frequently dismissed, and it is not solved — and the popular alternatives have not been shown to solve it either.
Active Research
Whether any identifiable subgroup benefits from adding T3, how to define adequate replacement beyond TSH, and who genuinely benefits from treating subclinical disease.
What Could Change Our Mind
A trial identifying a subgroup that reliably benefits from T3 combination therapy would change practice. Several have looked; none has yet found one.
The biggest myth
“Levothyroxine helps subclinical hypothyroidism”
The TRUST trial, in older adults with a raised TSH but normal free T4, found no improvement in symptoms or tiredness compared with placebo. Routine treatment of subclinical hypothyroidism is not supported, particularly in older people.
Ask BioSignal
Still have a question about levothyroxine?
Answers are retrieved from this record and the rest of the knowledge graph — never generated.
Why people take levothyroxine
Popularity is not evidence — but it is not stupid either. This explains the interest on its own terms.
Levothyroxine is one of the most prescribed drugs on earth, and it prompts two opposite questions. Millions wonder whether they need it when their TSH is only mildly raised — and often they don't. Others take it faithfully and still feel unwell, and are told that is impossible — which it isn't. Both groups deserve a straight answer.
If you're here because…
Jump straight to the part of the evidence that answers your question.
Approval, safety and regulatory
What it is approved for, who should be careful, what remains unknown — and the limits of what this evidence can tell you.
Regulatory status
FDA-approved for hypothyroidism
Availability
Prescription only
Sport (WADA)
Not a prohibited class (confirm at publication)
Known safety profile
Levothyroxine is very safe when correctly dosed — the hormone is one the body already makes. Essentially all of its harm comes from taking too much.
Common issues
- Symptoms of over-replacement: palpitations, tremor, anxiety, heat intolerance, weight loss
- Angina in people with underlying heart disease if started too high
Use caution if
- Older adults (start low, go slow)
- People with coronary heart disease
- People with adrenal insufficiency (this must be treated first)
- Pregnancy (requirements rise; needs close monitoring)
- People with atrial fibrillation or osteoporosis (over-replacement is especially harmful)
Long-term unknowns
The long-term consequences of treating mild subclinical disease — a large population — are not fully characterised, which is part of why routine treatment is not recommended.
Limits of this evidence
The evidence is strongest exactly where the disease is clearest. It thins at the margins — subclinical disease, persistent symptoms with a normal TSH — which is unfortunately where much of the clinical difficulty and nearly all of the commercial alternative-thyroid market lives.
Full regulatory and sport detail
- Regulatory approval
- Approved for hypothyroidism and for pituitary TSH suppression in specific settings.
- Approved indication
- Hypothyroidism.
- Research chemical
- N/A — a licensed medicine and one of the most prescribed drugs in the world.
- Sport (WADA)
- Not a WADA-prohibited class — confirm against the current list.
- Publication note
- Re-confirm regulatory status against primary sources at publication.
Demand, separated from evidence
Every claim people make about this, counted against what the evidence actually showed.
BioSignal evaluated 8 popular claims about levothyroxine.
Here is where each one landed — including the claims of harm, where “not established” is reassuring rather than damning.
- Supported by evidence
- 2
- Not established
- 6
Popularity is not evidence. This is simply a count of every claim BioSignal evaluated on this page, sorted by what the evidence actually showed — the full reasoning behind each verdict is in the Evidence Review below.
Supported by evidence
- Levothyroxine effectively treats overt hypothyroidism
- How and when you take levothyroxine matters
Not established
- Levothyroxine helps subclinical hypothyroidism
- Levothyroxine causes weight loss
- T4/T3 combination therapy is better than levothyroxine alone
- Desiccated thyroid extract is a better, more 'natural' option
- Persistent symptoms on levothyroxine with a normal TSH are imaginary
- Taking too much levothyroxine is harmless
The evidence review
Every claim with the reasoning behind its verdict, the doses actually studied, where scientists agree and disagree, and the questions still open.
What people claim
Every popular claim, with BioSignal’s verdict and how confident we are in it. The verdicts are always visible; open any claim to read the evidence behind it.
Levothyroxine effectively treats overt hypothyroidismSupportedHigh confidence
It restores thyroid hormone levels and resolves the symptoms of an underactive thyroid. This is among the most reliable treatments in medicine.
Levothyroxine causes weight lossNot establishedModerate confidence
Correcting genuine hypothyroidism may reverse the modest weight gain it caused, largely fluid. Levothyroxine is not a weight-loss drug, and using it as one is dangerous — it causes the harms of an overactive thyroid.
T4/T3 combination therapy is better than levothyroxine aloneNot establishedModerate confidence
Randomised trials have generally not shown combination therapy to be superior on objective measures, although some patients report preferring it. No subgroup that reliably benefits has been identified.
Desiccated thyroid extract is a better, more 'natural' optionNot establishedModerate confidence
Desiccated thyroid extract delivers a T3:T4 ratio that does not match human physiology, and its potency varies between batches. It is not recommended in guidelines, and 'natural' here means less consistent, not better.
Persistent symptoms on levothyroxine with a normal TSH are imaginaryNot establishedModerate confidence
A genuine subset of adequately treated patients continues to feel unwell. Dismissing them is not supported by evidence and is not good medicine. What is also true is that the popular alternatives have not been shown to help — the problem is real and unsolved, and both halves of that sentence matter.
Taking too much levothyroxine is harmlessNot establishedHigh confidence
Over-replacement produces a state resembling an overactive thyroid, increasing the risk of atrial fibrillation and accelerating bone loss. Over-treatment is common and is a genuine harm, not a theoretical one.
How and when you take levothyroxine mattersSupportedHigh confidence
Absorption is markedly affected by food, coffee, calcium, and iron. Taking it fasting and separating it from these substances is not a fussy detail — inconsistent absorption is a common reason for apparently unstable thyroid control.
Doses used in human studies
What was actually given to participants in the research. These are descriptions of studies, not recommendations.
Adults with overt hypothyroidism
- Intervention
- Oral levothyroxine, fasting
- Dose
- Clinician-titrated to TSH within the reference range
- Duration
- Usually lifelong
- Outcome
- Normalisation of TSH; symptom resolution
- Notes
- Titrated by TSH, typically rechecked around 6–8 weeks after any dose change
Older adults or those with heart disease
- Intervention
- Oral levothyroxine
- Dose
- Started low and increased slowly
- Duration
- Lifelong
- Outcome
- Symptom control without cardiac strain
- Notes
- Starting too high can precipitate angina or arrhythmia — a genuine reason for caution
Pregnancy
- Intervention
- Oral levothyroxine
- Dose
- Requirements typically increase
- Duration
- Throughout pregnancy, monitored closely
- Outcome
- Adequate maternal thyroid hormone for fetal development
- Notes
- Under-treatment in pregnancy has real consequences; requires close specialist monitoring
Adults with subclinical hypothyroidism
- Intervention
- Levothyroxine
- Dose
- Often not indicated
- Duration
- N/A
- Outcome
- No symptom benefit demonstrated in older adults (TRUST)
- Notes
- Treatment decisions are individualised — higher TSH values, positive antibodies, and pregnancy change the calculus
Where scientists agree — and don’t
Agreed
- Levothyroxine is the treatment of choice for overt hypothyroidism.
- TSH guides dosing in most patients.
- Over-replacement causes atrial fibrillation and bone loss and should be avoided.
- Absorption is affected by food, coffee, calcium, and iron.
- Desiccated thyroid extract is not recommended.
Debated
- Whether any subgroup benefits from adding T3.
- Which patients with subclinical hypothyroidism should be treated.
- Whether TSH alone adequately defines adequate replacement.
Unknown
- Why some adequately-treated patients remain symptomatic.
- Whether tissue-level thyroid status can differ from blood levels in a clinically meaningful way.
- The long-term consequences of treating mild disease.
What remains unknown
- Why do a subset of patients remain symptomatic despite a normal TSH — and what actually helps them?
- Is there an identifiable subgroup that genuinely benefits from T3?
- Which patients with subclinical hypothyroidism, if any, benefit from treatment?
- Does TSH alone adequately capture whether tissues are receiving enough thyroid hormone?
Questions people actually ask
What is levothyroxine?
Levothyroxine is a synthetic version of T4, the main hormone the thyroid produces. Your body converts it to the active hormone T3. Because it is identical to what the thyroid makes, replacement restores normal physiology rather than imitating it.
My TSH is slightly high but my T4 is normal. Do I need treatment?
Often, no. That pattern is subclinical hypothyroidism, and the TRUST trial in older adults found that levothyroxine produced no improvement in symptoms or tiredness compared with placebo. Treating it exposes you to the risks of over-replacement for a benefit that has not been demonstrated. There are exceptions — a markedly raised TSH, positive antibodies, or pregnancy change the picture — so it is a discussion, not a rule.
Why do I have to take it on an empty stomach?
Because absorption is genuinely sensitive to what is in your gut. Food, coffee, calcium, and iron all reduce it. This is not a fussy instruction — inconsistent absorption is one of the most common reasons thyroid control appears erratic, and it leads to dose changes that were never actually needed.
I still feel terrible even though my TSH is normal. What's going on?
This is a real and frustrating problem, and you are not imagining it — a genuine subset of adequately treated patients continues to feel unwell. What we must also say honestly is that the popular answers have not been shown to work: adding T3 has not proven superior in trials, and desiccated thyroid extract is less consistent, not better. The problem is real and it is unsolved. It is also worth checking the other things that cause these symptoms — anaemia, low B12, sleep apnoea, depression.
Is more levothyroxine better if I still feel tired?
No — and this is where real harm happens. Pushing the dose above what you need produces a state like an overactive thyroid, which increases the risk of atrial fibrillation and thins your bones. Over-treatment is common, and tiredness has many causes other than an under-treated thyroid.
Practical takeaways
- For overt hypothyroidism, levothyroxine is cheap, effective, and genuinely transformative.
- For subclinical hypothyroidism, treatment often adds risk without benefit — TRUST found no symptom improvement.
- Over-replacement is a real harm: atrial fibrillation and bone loss, not just an abnormal number.
- Take it fasting and away from coffee, calcium, and iron — absorption really is that sensitive.
- Persistent symptoms on a normal TSH are real and unsolved; T3 and desiccated thyroid have not been shown to solve them.
How it works
The mechanism comes last on purpose. A compelling explanation of how something might work is the easiest part of the story to tell, and the part most likely to outlive the evidence for it.
Levothyroxine is identical to the T4 the thyroid produces, and the body converts it to active T3. Replacement restores normal physiology rather than mimicking it.
How we found out
Thyroid Physiology Established
The hypothalamic–pituitary–thyroid axis was characterised, and the exquisitely sensitive log-linear relationship between TSH and thyroid hormone made TSH the ideal first-line test.
Synthetic T4 Replacement
Levothyroxine replaced animal-derived thyroid extract as the standard of care, offering consistent potency and physiological replacement — one of endocrinology's clear success stories.
The Subclinical Question
As TSH testing became widespread, large numbers of people were identified with a raised TSH but normal T4, and treatment expanded ahead of the evidence that it helped.
TRUST and the Limits of Treatment
A randomised trial in older adults with subclinical hypothyroidism found no improvement in symptoms or tiredness, prompting a re-examination of who genuinely benefits from treatment.
References
Verified sources. BioSignal does not print a citation it has not checked.
References for this record are being verified and will be published with the next review. BioSignal does not print citations it has not checked.
Version history
Version 1.0
Initial record for the Hormonal Health Ecosystem, authored to the Creatine benchmark. Calibration: Established maturity, high confidence for overt disease — with the subclinical over-treatment problem and the unsolved persistent-symptoms problem both stated plainly rather than smoothed over. Review cadence: Annually.
Continue exploring
Three places this record leads next.